Total Payments
$333.53
2024 Payments
$20.13
Companies
11
Transactions
21
Medicare Patients
1,402
Medicare Billing
$59,426
Payment Breakdown by Category
Food & Beverage$333.53 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $333.53 | 21 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | $77.63 | 5 | $0 (2023) |
| Amgen Inc. | $48.50 | 3 | $0 (2022) |
| GlaxoSmithKline, LLC. | $42.07 | 2 | $0 (2024) |
| AbbVie Inc. | $32.90 | 2 | $0 (2021) |
| Novo Nordisk Inc | $32.17 | 2 | $0 (2021) |
| Merck Sharp & Dohme LLC | $28.95 | 2 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.45 | 1 | $0 (2023) |
| DEXCOM, INC. | $15.02 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $14.10 | 1 | $0 (2023) |
| Biogen, Inc. | $11.99 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20.13 | 1 | GlaxoSmithKline, LLC. ($20.13) |
| 2023 | $67.54 | 4 | GlaxoSmithKline, LLC. ($21.94) |
| 2022 | $75.55 | 5 | Amgen Inc. ($48.50) |
| 2021 | $170.31 | 11 | Kowa Pharmaceuticals America, Inc. ($64.58) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/13/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: VACCINES | ||||||
| 11/07/2023 | Kowa Pharmaceuticals America, Inc. | LIVALO (Drug) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/18/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/08/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Gastroenterology | ||||||
| 08/16/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $11.75 | General |
| Category: Cardio-renal | ||||||
| 08/03/2022 | Merck Sharp & Dohme LLC | BELSOMRA (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: NEUROSCIENCE | ||||||
| 08/02/2022 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: Inflammation | ||||||
| 03/29/2022 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Inflammation | ||||||
| 02/02/2022 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Inflammation | ||||||
| 10/21/2021 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: NEUROLOGY | ||||||
| 10/14/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Diabetes | ||||||
| 09/15/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: NEUROSCIENCE | ||||||
| 06/24/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $18.71 | General |
| Category: Cardiovascular | ||||||
| 05/13/2021 | Merck Sharp & Dohme Corporation | BELSOMRA (Drug), JANUVIA | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: NEUROSCIENCE | ||||||
| 05/10/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: NEUROSCIENCE | ||||||
| 05/06/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $17.18 | General |
| Category: Cardiovascular | ||||||
| 04/21/2021 | DEXCOM, INC. | DEXCOM G6 TRANSMITTER (Device) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: ENDOCRINOLOGY | ||||||
| 03/11/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $16.70 | General |
| Category: Cardiovascular | ||||||
| 02/18/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $11.99 | General |
| Category: Cardiovascular | ||||||
| 02/04/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 420 | 701 | $44,428 | $16,519 |
| 2022 | 7 | 313 | 481 | $41,330 | $17,936 |
| 2021 | 13 | 393 | 579 | $41,460 | $16,838 |
| 2020 | 6 | 276 | 421 | $23,868 | $8,132 |
Total Patients
1,402
Total Services
2,182
Medicare Billing
$59,426
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 190 | 291 | $31,137 | $11,750 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 43 | $6,837 | $2,407 | 35.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 29 | 32 | $2,048 | $725.95 | 35.4% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 16 | 32 | $640.00 | $496.40 | 77.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 47 | 68 | $2,652 | $483.80 | 18.2% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 24 | 78 | $663.00 | $329.81 | 49.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 24 | 25 | $235.00 | $196.00 | 83.4% |
| 81002 | Urinalysis, manual test | Office | 2023 | 27 | 28 | $112.00 | $95.48 | 85.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 23 | 104 | $104.00 | $34.48 | 33.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 185 | 311 | $33,277 | $14,608 | 43.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 31 | $4,929 | $1,913 | 38.8% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 17 | 34 | $680.00 | $529.16 | 77.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 15 | 16 | $1,024 | $465.70 | 45.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 22 | 30 | $1,170 | $227.49 | 19.4% |
| 81002 | Urinalysis, manual test | Office | 2022 | 35 | 45 | $180.00 | $151.30 | 84.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 13 | 14 | $70.00 | $41.43 | 59.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 150 | 228 | $24,396 | $11,072 | 45.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 39 | 44 | $6,996 | $2,356 | 33.7% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 13 | 13 | $1,037 | $863.59 | 83.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 31 | 35 | $2,240 | $690.28 | 30.8% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 14 | 14 | $2,002 | $619.48 | 30.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 36 | 55 | $2,145 | $427.70 | 19.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 20 | 23 | $1,495 | $214.38 | 14.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 13 | 13 | $507.00 | $206.18 | 40.7% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2021 | 12 | 36 | $306.00 | $196.41 | 64.2% |
About Courtney Wright
Courtney Wright is a Adult Health healthcare provider based in Boaz, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/25/2019. The National Provider Identifier (NPI) number assigned to this provider is 1770040941.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Courtney Wright has received a total of $333.53 in payments from pharmaceutical and medical device companies, with $20.13 received in 2024. These payments were reported across 21 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($333.53).
As a Medicare-enrolled provider, Wright has provided services to 1,402 Medicare beneficiaries, totaling 2,182 services with total Medicare billing of $59,426. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Adult Health
- Location Boaz, AL
- Active Since 02/25/2019
- Last Updated 02/25/2019
- Taxonomy Code 363LA2200X
- Entity Type Individual
- NPI Number 1770040941
Products in Payments
- Livalo (Drug) $64.58
- Otezla (Drug) $48.50
- UBRELVY (Drug) $32.90
- RYBELSUS (Drug) $32.17
- BELSOMRA (Drug) $28.95
- SHINGRIX (Biological) $21.94
- AREXVY (Drug) $20.13
- TRULANCE (Drug) $18.45
- DEXCOM G6 TRANSMITTER (Device) $15.02
- FARXIGA (Drug) $14.10
- LIVALO (Drug) $13.05
- ADUHELM (Biological) $11.99
- Kerendia (Drug) $11.75
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.